drugset

drugset / Trial / NCT01159223

Low Dose Atazanavir/r Versus Standard Dose Atazanavir/r (LASA)

NCT01159223 ↗

Phase 4 Completed 559 enrolled The HIV Netherlands Australia Thailand Research Collaboration Kirby Institute · collab National Health Security Office, Thailand · collab

RandomizedParallel-groupTriple-blindTreatment

Summary

This study will compare the efficacy and safety of ATV/r at either 200/100 mg or 300/100mg given daily in Thai patients in combination with 2NRTIs.

Timeline

Start: 2011-05
Primary completion: 2014-12
Completion: 2015-06

Publications

Results Bunupuradah T, Kiertiburanakul S, Avihingsanon A, Chetchotisakd P, Techapornroong M, Leerattanapetch N, Kantipong P, Bowonwatanuwong C, Banchongkit S, Klinbuayaem V, Mekviwattanawong S, Nimitvilai S, Jirajariyavej S, Prasithsirikul W, Munsakul W, Bhakeecheep S, Chaivooth S, Phanuphak P, Cooper DA, Apornpong T, Kerr SJ, Emery S, Ruxrungtham K; LASA Study Group. Low-dose versus standard-dose ritonavir-boosted atazanavir in virologically suppressed Thai adults with HIV (LASA): a randomised, open-label, non-inferiority trial. Lancet HIV. 2016 Aug;3(8):e343-e350. doi: 10.1016/S2352-3018(16)30010-8. Epub 2016 May 24.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Atazanavir	Other / unclassified	200 mg	Oral
Subject	Atazanavir	Other / unclassified	300 mg	Oral
Background	Ritonavir	Other / unclassified	100 mg	Oral

Indications